{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:50:13Z","timestamp":1789487413324,"version":"build-2803163510"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01292"],"award-info":[{"award-number":["PI21\/01292"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["AC22\/00029"],"award-info":[{"award-number":["AC22\/00029"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["INT23\/00078"],"award-info":[{"award-number":["INT23\/00078"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01510"],"award-info":[{"award-number":["PI24\/01510"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Agency for Management of University and Research Grants","doi-asserted-by":"publisher","award":["2021 SGR 00883"],"award-info":[{"award-number":["2021 SGR 00883"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sparsentan has demonstrated significant antiproteinuric effects in randomized trials of IgA nephropathy (IgAN). However, real-world evidence remains scarce and is largely limited to short-term follow-up. Data on the durability of the antiproteinuric response in routine clinical practice are still lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective study included patients with biopsy-proven IgAN treated with sparsentan in routine clinical practice across Spanish centers. Patients were eligible if they initiated sparsentan outside a clinical trial and had at least 3 months of follow-up. The primary outcome was the proportion of patients achieving a\u00a0&amp;gt;50% reduction in proteinuria at 3 months (responders). Secondary outcomes included changes in proteinuria and kidney function at 6 and 12 months, as well as safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 41 patients were included. The median age was 42 years, with a median baseline estimated glomerular filtration rate (eGFR) of 44\u00a0ml\/min\/1.73 m2 and 95% receiving concomitant sodium\u2013glucose cotransporter-2 (SGLT2) inhibitors. Median baseline proteinuria was 1163\u00a0mg\/24\u00a0h. At 3 months, proteinuria decreased to 772\u00a0mg\/24\u00a0h (median reduction 44.1%), with 51% of patients achieving a\u00a0&amp;gt;50% reduction. Among patients with extended follow-up, the antiproteinuric effect was sustained at 6 months (median reduction 46.9%) and persisted at 12 months (median reduction 38.9%), despite increased variability. Notably, kidney function remained stable throughout follow-up, despite a moderately reduced baseline eGFR. No clinically relevant hyperkalemia or severe adverse events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this multicenter real-world Spanish cohort, sparsentan was associated with a sustained reduction in proteinuria in patients with biopsy-proven IgAN, maintained up to 12 months, along with preserved kidney function even in those with moderately reduced baseline eGFR, and a favorable safety profile. These findings support the effectiveness of sparsentan on top of contemporary standard of care and provide early evidence of sustained benefit in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag298","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:04:59Z","timestamp":1788264299000},"source":"Crossref","is-referenced-by-count":0,"title":["Twelve-month real-world outcomes of sparsentan in a multicenter Spanish IgA nephropathy cohort"],"prefix":"10.1093","volume":"19","author":[{"given":"Clara","family":"Garc\u00eda-Carro","sequence":"first","affiliation":[{"name":"San Carlos Clinical University Hospital, National Reference Centre for Complex Glomerular Diseases (CSUR), IdISSC Nephrology Department, , Madrid ,","place":["Spain"]},{"name":"Complutense University Department of Medicine, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antolina","family":"Rodr\u00edguez-Moreno","sequence":"additional","affiliation":[{"name":"San Carlos Clinical University Hospital, National Reference Centre for Complex Glomerular Diseases (CSUR), IdISSC Nephrology Department, , Madrid ,","place":["Spain"]},{"name":"Complutense University Department of Medicine, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Cordero","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Jim\u00e9nez D\u00edaz Nephrology Department, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4558-5236","authenticated-orcid":false,"given":"Mar\u00eda Vanessa","family":"P\u00e9rez-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Jim\u00e9nez D\u00edaz Nephrology Department, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3454-5837","authenticated-orcid":false,"given":"Helena Marco","family":"Rusi\u00f1ol","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3 Puigvert Nephrology Department, , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Pasache","sequence":"additional","affiliation":[{"name":"Marqu\u00e9s de Valdecilla Hospital Nephrology Department, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Morales","sequence":"additional","affiliation":[{"name":"San Carlos Clinical University Hospital, National Reference Centre for Complex Glomerular Diseases (CSUR), IdISSC Nephrology Department, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Zamora","sequence":"additional","affiliation":[{"name":"Villalba General University Hospital Nephrology Department, , Villalba ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0042-4765","authenticated-orcid":false,"given":"Diego","family":"Parra","sequence":"additional","affiliation":[{"name":"Gregorio Mara\u00f1\u00f3n General University Hospital Nephrology Department, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Villa","sequence":"additional","affiliation":[{"name":"Badajoz University Hospital Nephrology Department, , Badajoz ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8718-5858","authenticated-orcid":false,"given":"Elena","family":"Guill\u00e9n-Olmos","sequence":"additional","affiliation":[{"name":"National Reference Centre for Complex Glomerular Diseases (CSUR), Hospital Cl\u00ednic Barcelona\u2013University of Barcelona Nephrology and Kidney Transplantation Department, , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Coll-Brito","sequence":"additional","affiliation":[{"name":"Germans Trias i Pujol Hospital Nephrology Department, , Badalona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Don Benito Hospital Nephrology Department, , Villanueva ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Bordignon","sequence":"additional","affiliation":[{"name":"Bellvitge University Hospital, Hospitalet de Llobregat Nephrology Department, ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Arcal","sequence":"additional","affiliation":[{"name":"Consorci Sanitari de l\u2019Anoia Nephrology Department, , Igualada ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Gracia","sequence":"additional","affiliation":[{"name":"Miguel Servet University Hospital Nephrology Department, , Zaragoza ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Delgado","sequence":"additional","affiliation":[{"name":"Canarias University Hospital Nephrology Department, , Tenerife ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3621-0766","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Soler","sequence":"additional","affiliation":[{"name":"Vall d\u2019Hebron University Hospital, National Reference Centre for Complex Glomerular Diseases (CSUR) Nephrology Department, , RICORS 2040, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-9729","authenticated-orcid":false,"given":"Ana I","family":"S\u00e1nchez-Fructuoso","sequence":"additional","affiliation":[{"name":"San Carlos Clinical University Hospital, National Reference Centre for Complex Glomerular Diseases (CSUR), IdISSC Nephrology Department, , Madrid ,","place":["Spain"]},{"name":"Complutense University Department of Medicine, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2026091510212540300_bib1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"key":"2026091510212540300_bib2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"2026091510212540300_bib3","volume-title":"KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)","author":"Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group"},{"key":"2026091510212540300_bib4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026091510212540300_bib5","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2026091510212540300_bib6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.2215\/CJN.0000000961","article-title":"Association between complete proteinuria remission and kidney function in the phase 3 PROTECT trial of sparsentan in IgA nephropathy","volume":"21","author":"Heerspink","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026091510212540300_bib7","doi-asserted-by":"publisher","first-page":"1461879","DOI":"10.3389\/fmed.2024.1461879","article-title":"Therapy of IgA nephropathy: time for a paradigm change","volume":"11","author":"Barratt","year":"2024","journal-title":"Front Med"},{"key":"2026091510212540300_bib8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"2026091510212540300_bib9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","author":"EMPA-KIDNEY Collaborative Group","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091510212540300_bib10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"2026091510212540300_bib11","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"2026091510212540300_bib12","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"2026091510212540300_bib13","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"2026091510212540300_bib14","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"2026091510212540300_bib15","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"2026091510212540300_bib16","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1681\/ASN.2020030349","article-title":"Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy","volume":"32","author":"Canney","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026091510212540300_bib17","doi-asserted-by":"publisher","first-page":"sfae394","DOI":"10.1093\/ckj\/sfae394","article-title":"First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors","volume":"18","author":"Schanz","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026091510212540300_bib18","doi-asserted-by":"publisher","first-page":"1673799","DOI":"10.3389\/fneph.2025.1673799","article-title":"Maximizing the anti-proteinuric response: a multicenter real-world sparsentan case series in IgA disorders","volume":"5","author":"Ray","year":"2025","journal-title":"Front Nephrol"},{"key":"2026091510212540300_bib19","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2215\/CJN.0000000961","article-title":"Association between complete proteinuria remission and kidney function in the phase 3 PROTECT trial of sparsentan in IgA nephropathy","volume":"21","author":"Heerspink","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026091510212540300_bib20","doi-asserted-by":"publisher","first-page":"sfag162","DOI":"10.1093\/ckj\/sfag162","article-title":"Long-term real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors","volume":"19","author":"Schanz","year":"2026","journal-title":"Clin Kidney J"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag298\/70893389\/sfag298.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/9\/sfag298\/70893389\/sfag298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/9\/sfag298\/70893389\/sfag298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:25:16Z","timestamp":1789482316000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag298\/8778463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag298","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"sfag298"}}